Loxo Oncology: Out Of The Frying Pan And Into The Fire, Part 1 [Seeking Alpha]
LOXO ONCOLOGY (LOXO)
Last loxo oncology earnings: 11/8 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.loxooncology.com
Company Research
Source: Seeking Alpha
Summary Loxo Oncology ( LOXO ) is a clinical-stage biopharmaceutical company developing precision, small molecule inhibitors to treat cancer. On May 29, 2018, the FDA accepted the New Drug Application (NDA) for Larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring an NTRK gene fusion. The FDA granted larotrectinib priority review with a target action date of November 26, 2018. Following-up on stellar results for their second drug, LOXO-292 which were presented at the American Society of Clinical Oncology (ASCO) 2018 meeting, the company announced in their Q2 earnings call that they are pursuing a timeline to submit at 2019 NDA for LOXO-292. This timeline would make it one of the fastest drugs ever developed for an oncology indication, with ~2-3 years from first-in-human trials to a marketing approval. Loxo has generated incredible returns for investors, with the stock price soaring over 300% in 18 months.
Show less
Read more
Impact Snapshot
Event Time:
LOXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LOXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LOXO alerts
High impacting LOXO ONCOLOGY news events
Weekly update
A roundup of the hottest topics